Fig. 5From: Nanotechnology based solutions for anti-leishmanial impediments: a detailed insighta Inadequate intestinal absorption of traditional anti-leishmanial drugs. b Improved M-cells mediated intestinal absorption, hepatic accumulation and oral bioavailability, hence, passive VL targeting could be achieved using anti-leishmanial nano-DDSBack to article page